Abramson Cancer Center at ESMO 2026

Oct 23–27, 2026 Madrid, Spain ~37k attendees Website

Abramson Cancer Center takes part in 3 sessions at ESMO 2026 in Madrid. Its sessions focus on new targeted drugs in ovarian cancer, mesothelioma and other solid tumours, alongside renal and urothelial cancers. It presents survival data for azenosertib in platinum-resistant ovarian cancer and first-in-human results for a pan-TEAD inhibitor designed with artificial intelligence.

OrganizationESMO 2026 Attendance
Abramson Cancer Center
Philadelphia, PA
pennmedicine.org
Cancer centre & hospital
US National Cancer Institute-designated comprehensive cancer centre of the University of Pennsylvania and Penn Medicine in Philadelphia, Pennsylvania.
Abstract
Fri Oct 23
16:47–16:52
Abstract
Sun Oct 25
08:57–09:02
Abstract
Sun Oct 25
09:00–09:12
Invited Discussant 3586O, 3587O and LBA88
Proffered paper 2: Genitourinary tumours, renal and urothelial
Genitourinary cancers

Explore the full ESMO 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Madrid. Leave your work email and we’ll be in touch.

Privacy

Download the full ESMO 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from Abramson Cancer Center

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction